A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 10 2021
15 10 2021
Historique:
received:
19
05
2021
revised:
29
06
2021
accepted:
22
07
2021
pubmed:
28
7
2021
medline:
2
4
2022
entrez:
27
7
2021
Statut:
ppublish
Résumé
To address the need for clinical investigators in oncology, American Association for Cancer Research (AACR) and American Society for Clinical Oncology (ASCO) established the Methods in Clinical Cancer Research Workshop (MCCRW). The workshop's objectives were to: (i) provide training in the methods, design, and conduct of clinical trials; (ii) ensure that clinical trials met federal and international ethical guidelines; (iii) evaluate the effectiveness of the workshop; and (iv) create networking opportunities for young investigators with mentoring senior faculty. Educational methods included: (i) didactic lectures, (ii) Small Group Discussion Sessions, (iii) Protocol Development Groups, and (iv) one-on-one mentoring. Learning focused on the development of an Institutional Review Board (IRB)-ready protocol, which was submitted on the last day of the workshop. Evaluation methods included: (i) pre- and postworkshop tests, (ii) students' workshop evaluations, (iii) faculty's ratings of protocol development, (iv) students' productivity in clinical research after the workshop, and (v) an independent assessment of the workshop. From 1996 to 2014, 1,932 students from diverse backgrounds attended the workshop. There was a significant improvement in the students' level of knowledge from the pre- to the postworkshop exams (
Identifiants
pubmed: 34312215
pii: 1078-0432.CCR-21-1799
doi: 10.1158/1078-0432.CCR-21-1799
pmc: PMC8530870
mid: NIHMS1729164
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
5472-5481Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA068647
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
J Clin Oncol. 2007 Apr 20;25(12):1468-9
pubmed: 17360965
Curr Oncol Rep. 2005 Jul;7(4):307-11
pubmed: 15946591
JAMA. 2007 Jun 13;297(22):2496-501
pubmed: 17565084
Clin Cancer Res. 2006 Jun 15;12(12):3661-97
pubmed: 16778094
Clin Cancer Res. 2005 Apr 15;11(8):2785-808
pubmed: 15837727
Cancer Treat Rev. 2019 Jun;76:33-40
pubmed: 31108240
J Cancer Educ. 2013 Mar;28(1):9-17
pubmed: 23292841
Am Soc Clin Oncol Educ Book. 2019 Jan;39:176-184
pubmed: 31099620
Clin Cancer Res. 2013 Aug 15;19(16):4305-8
pubmed: 23833307
N Engl J Med. 1979 Dec 6;301(23):1254-9
pubmed: 503128
Ochsner J. 2020 Spring;20(1):44-49
pubmed: 32284682
Clin Cancer Res. 2006 Dec 15;12(24):7209-14
pubmed: 17189391
N Engl J Med. 2013 Nov 14;369(20):1877-80
pubmed: 24224621
Cancer Res. 2013 Jan 15;73(2):519-28
pubmed: 23329644
J Natl Cancer Inst. 2010 Sep 8;102(17):1371
pubmed: 20682918
Acad Med. 2012 Mar;87(3):266-70
pubmed: 22373616
Acad Med. 2009 Apr;84(4):439-45
pubmed: 19318774
Nat Rev Drug Discov. 2016 Dec;15(12):817-818
pubmed: 27811931
Clin Cancer Res. 2005 Aug 15;11(16):5661-2
pubmed: 16115898
Clin Cancer Res. 2004 Oct 15;10(20):6759-63
pubmed: 15501951
J Thorac Oncol. 2007 Jan;2(1):1-2
pubmed: 17410001
Mol Cancer Ther. 2007 Apr;6(4):1180-5
pubmed: 17431101
JAMA. 2016 Apr 12;315(14):1453-4
pubmed: 27115263
J Natl Cancer Inst. 2011 Apr 20;103(8):636-44
pubmed: 21422403
Adv Cancer Res. 2020;146:139-166
pubmed: 32241387
J Natl Cancer Inst. 2006 Sep 20;98(18):1272-4
pubmed: 16985244
N Engl J Med. 2005 Jan 20;352(3):293-7
pubmed: 15659733
JAMA. 1998 Oct 28;280(16):1427-31
pubmed: 9801003
Nature. 2008 Jun 12;453(7197):840-2
pubmed: 18548043
JAMA. 2012 Nov 21;308(19):1981-2
pubmed: 23168821
Clin Cancer Res. 2007 Apr 15;13(8):2307-8
pubmed: 17438086
Nat Rev Drug Discov. 2009 Jan;8(1):15-6
pubmed: 19008887
FASEB J. 2014 Mar;28(3):1049-58
pubmed: 24297696
JAMA. 2003 Mar 12;289(10):1278-87
pubmed: 12633190
JAMA Oncol. 2016 Sep 1;2(9):1209-16
pubmed: 27270617
J Clin Oncol. 2003 Apr 1;21(7):1404-11
pubmed: 12663734
Am J Clin Oncol. 2007 Oct;30(5):549-55
pubmed: 17921718
Clin Cancer Res. 2013 Jan 15;19(2):491-9
pubmed: 23204130
Nat Rev Drug Discov. 2003 Aug;2(8):609-10
pubmed: 12908467
Eur J Cancer. 2004 Jan;40(2):173-5
pubmed: 14728928
Clin Cancer Res. 2012 Feb 1;18(3):638-44
pubmed: 22298897
Clin Pharmacol Ther. 2010 Dec;88(6):765-73
pubmed: 20981005
Int J Equity Health. 2019 Jun 18;18(1):93
pubmed: 31215424
Clin Cancer Res. 2007 Apr 15;13(8):2400-5
pubmed: 17438099
Nat Rev Clin Oncol. 2011 Nov 08;9(4):199-207
pubmed: 22064459
BMC Cancer. 2019 Aug 14;19(1):808
pubmed: 31412805
N Engl J Med. 2006 Feb 2;354(5):496-507
pubmed: 16452561
Oncologist. 2010;15 Suppl 1:19-23
pubmed: 20237213
N Engl J Med. 2003 Nov 6;349(19):1860-5
pubmed: 14602885
Clin Pharmacol Ther. 2014 May;95(5):483-5
pubmed: 24747238
Clin Ther. 2013 Dec;35(12):1865-6
pubmed: 24332195
J Clin Oncol. 2007 Aug 10;25(23):3482-7
pubmed: 17687153